This drug is safe with no deaths reported in two decades on trial. Yet because of rare disease studies have small cohorts. Traditional statistical thresholds can overlook meaningful improvements. Without FDA approval or continued compassionate use, patients will face rapid decline, loss of essential abilities and preventable sufferings and death. I urge the FDA to recognize the proven, sustained benefits of Adalurin and act swiftly to secure ongoing access for all who need it. (12:52–13:01)
CLAIM
Asserts that lack of FDA approval or compassionate use of Adalarn will lead to decline and preventable suffering for patients.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
